Hakop Gevorkyan, MD
Internal Medicine · Burbank, CANPI 1073689386
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 49.6% of the total. 2025 is the largest year on record at $356, 4.6 times the $77 reported in 2019.
Across 20 payments — averaging $31.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$316
- AbbVie$108
- Astellas Pharma US Inc$55
- Novo Nordisk$50
- Philips North America LLC$24
- Takeda Pharmaceuticals U.S.A., Inc.$23
- plus $60 from 3 others
Across 55 payments — averaging $86,414 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.2M
- Sanofi US Services Inc.$920K
- Novartis$536K
- LEO Pharma AS$536K
- Vertex$350K
- Neurocrine Biosciences, Inc.$111K
- plus $96K from 2 others
What the payments were for
- Food & beverage$636100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $316 |
| AbbVie | 6 | $108 |
| Astellas Pharma US Inc | 3 | $55 |
| Novo Nordisk | 2 | $50 |
| Philips North America LLC | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$293
How this compares
$636 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 160 | $265,901 |
| JanumetSitagliptin Phos/Metformin Hcl | 305 | $165,835 |
| EliquisApixaban | 342 | $151,437 |
| JanuviaSitagliptin Phosphate | 269 | $147,172 |
| OzempicSemaglutide | 148 | $146,839 |
| Diclofenac Sodium | 373 | $137,768 |
| JardianceEmpagliflozin | 225 | $124,291 |
| Diclofenac Potassium | 47 | $123,364 |
| LinzessLinaclotide | 157 | $89,580 |
| ProliaDenosumab | 47 | $81,089 |
| TradjentaLinagliptin | 155 | $68,199 |
| TrulicityDulaglutide | 69 | $65,051 |
| Zileuton ErZileuton | 19 | $60,891 |
| Metformin Er GastricMetformin Hcl | 40 | $56,005 |
| VascepaIcosapent Ethyl | 195 | $52,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $50 | $161,780165 claims |
| AbbVieLinzess, Creon, Restasis | $108 | $132,091215 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $23 | $86,36889 claims |
| AmgenProlia | $316 | $81,08947 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $27,67364 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Burbank
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.